Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors
This report underlines the importance of the awareness on endocrine irAEs with ICIs, particularly life-threatening DKA. A baseline assessment of glycemia and glycated hemoglobin is mandatory, and we recommend a close monitoring of glycemic trend over time during ICIs therapy. Patients and their caregivers should be informed and counselled to recognise DKA signs and symptoms.
Authors
- Enrica T. Tanda (ORCID: https://orcid.org/0000-0002-1552-9826)
- Francesco Cocchiara (ORCID: https://orcid.org/0009-0000-0115-5555)
- Alessandro Pastorino (ORCID: https://orcid.org/0000-0003-4207-3665)
- Mara Boschetti (ORCID: https://orcid.org/0000-0002-9383-0913)
- Lara Vera
- Diego Ferone (ORCID: https://orcid.org/0000-0002-1410-6143)
- Anna Arecco (ORCID: https://orcid.org/0000-0002-6059-3982)
- Davide Carlo Maggi (ORCID: https://orcid.org/0000-0003-3928-1295)
- Federico Gatto (ORCID: https://orcid.org/0000-0002-5062-9208)
- Cristian Petolicchio (ORCID: https://orcid.org/0009-0002-9541-788X)
Institutions
- Ospedale Policlinico San Martino (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-03-25
- DOI
- https://doi.org/10.3389/fendo.2025.1550702
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09